ZEAB Eight Design Modules
Cambridge, UK – 21 July 2020 – Cresset Discovery Services, a leading early phase discovery CRO, has teamed up with ZEAB Therapeutic to advance colorectal cancer treatments using advanced computational tools. This collaboration has produced valuable models, ZEAB 1-8, to propel further research and drug development. With colorectal cancer being the third most common cancer globally, this partnership aims to address a critical need for innovative treatments and improve patient outcomes.
Our Response to COVID - 19
ZEAB Therapeutic Limited is proud to announce its involvement in COVID-19 research and treatment development. We are working on two innovative therapies: a natural, immune-boosting drug to fight COVID-19 and a gene therapy to regulate gene expression. These treatments will be thoroughly tested using various models. Our research aims to address the severe impact of COVID-19, especially on vulnerable populations, by focusing on the crucial role of phase II detoxifying enzymes in combating oxidative stress and infection progression.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.